ABT-737

Catalog No.S1002

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Cited by 120 Publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )
Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )
Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )
PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )
Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NVniZmlXS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHP2T4kzPTBibl5CpC=>	NHy5[Zg4OiCq	NUnQdm91TE2VTx?=	MWPjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigRmNNPiC\|aWLORS=>	M{fPXFI3PjV5Mki4
KG1a	NGnrS\|RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVHadm86OC1zMDFOwG0>	NF3uO4wzPCCq	NHPPS4lFVVOR	NU\IO4NuUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIjYd2IzPjV3MkexNi=>
Kasumi-1	MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmDsNE0yOCEQvF2=	MX2yOEBp	MX7EUXNQ	NU\IZnVJUUN3ME20Mlg4KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NVSzV4J2OjZ3NUK3NVI>
KG1a	MYDBdI9xfG:\|aYOgRZN{[Xl?	MV:wMVExKM7:TR?=	MVKyOEBp	MYfEUXNQ	NUjS[IN6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWSyOlU2OjdzMh?=
Kasumi-1	MUfBdI9xfG:\|aYOgRZN{[Xl?	NITqR4YxNTFyIN88US=>	NF\6N3kzPCCq	MYXEUXNQ	M2PZeYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVyyOlU2OjdzMh?=
MC-3	M{L6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7CeHk2NzFyL{KwJO69VQ>?	MnmxNlQhcA>?	MWHEUXNQ	Mn\6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NWCwOI9bOjZ2NEe2NVU>
HN22	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljxNk42NzdwNT:yNk42KM7:TR?=	NFf2SY0zPCCq	Mn7tSG1UVw>?	NHP1ZWRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYiyOlQ1PzZzNR?=
MC-3	NHi2cnlCeG:ydH;zbZMhSXO\|YYm=	NUD6bmR7PS9zMD:yNEDPxE1?	M1O0S\|I1KGh?	M3jZSmROW09?	NUjIN4JXcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=>	NYPt[4tbOjZ2NEe2NVU>
HN22	NWPjW5pPSXCxcITvd4l{KEG\|c3H5	MVqyMlUwPy53L{KyMlUh\|ryP	M2nONlI1KGh?	M2LJO2ROW09?	M2TidIlv\HWlZYOgZ4F{eGG\|ZT3t[YRq[XSnZDDhdI9xfG:\|aYO=	NEDwW5AzPjR2N{[xOS=>
MOLT-4	NV;CdVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnFNVAuPTByMDDuUS=>	NUnjPXhLPzJiaB?=	MoHXSG1UVw>?	NIrneVdKSzVyPUCuNVk5KM7:TR?=	M3PaR\|I3Ozl{M{Oy
RS4;11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3GWldvOTBvNUCwNEBvVQ>?	NELl[mU4OiCq	MUjEUXNQ	MkDyTWM2OD1yLkCwNkDPxE1?	NGf3ZnIzPjN7MkOzNi=>
JURKAT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNE02ODByIH7N	Mo\xO\|IhcA>?	M2TTS2ROW09?	MYrJR\|UxRTZ4IN88US=>	NWrQXJFROjZ\|OUKzN\|I>
CEM R	NIHyfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4mxTlExNTVyMECgcm0>	NFvGflg4OiCq	MYXEUXNQ	M4PUcWlEPTB;NT60JO69VQ>?	NEPJdnEzPjN7MkOzNi=>
CEM S	M2npPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\DcYUyOC13MECwJI5O	MlrCO\|IhcA>?	NXrRd\|J1TE2VTx?=	MlfZTWM2OD1zMj6xJO69VQ>?	NEDKUXYzPjN7MkOzNi=>
MOLT-4	Mo\4RZBweHSxc3nzJGF{e2G7	MnTuNVAuOTByMDDuUS=>	NI\EVGozPCCq	NIHPfXhFVVOR	NHvSZ2Fk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	M{exWlI3Ozl{M{Oy
CEM S	Mor6RZBweHSxc3nzJGF{e2G7	MmPUNVAuOTByMDDuUS=>	NHjWWIIzPCCq	M4PqSmROW09?	M4rVUINifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	M2f3RlI3Ozl{M{Oy
JURKAT	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWm3RYoxOTByLUGwNFAhdk1?	Mn3rOFghcA>?	NWTGXZE{TE2VTx?=	Mn;lTWM2OD17NUZCtVkvOyCwTR?=	NE\1TlgzPjF5MkK2PS=>
LOUCY	M4rDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDMNVAxNTFyMECgcm0>	MXq0PEBp	M1\vPGROW09?	NWjJSpZ6UUN3ME2zNk45yrFzMD65JI5O	Mkj6NlYyPzJ{Nkm=
WM-115	NFTvO\|RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVTnTmk2OTBywrDuUS=>	MoPqO\|IhcA>?		MUTlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	MU[yOlEyPjd5Nh?=
B16	M{j5WWNmdGxiVnnhZoltcXS7IFHzd4F6	MlXvNVAxyqCwTR?=	MmDjO\|IhcA>?		NHTLSXlmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?=	NX\tVohUOjZzMU[3O\|Y>
HL-60	NHnjW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV23NkBp		M3jnTWlEPTEEoE2gNVAvPyCwTR?=	M4XXXFI3ODR3NkC5
MOLM-13	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVHMcpBMPzJiaB?=		NVzU[Wc6UUN3MNMgQUAzPy57IH7N	NHXleVEzPjB2NU[wPS=>
OCI-AML3	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2HsRVczKGh?		M12wUmlEPTEEoE2gNVk2OCCwTR?=	Mm\5NlYxPDV4MEm=
BCWM.1	MkfBRZBweHSxc3nzJGF{e2G7	NW\NW3E3OC1zLk[g{txO	MonaNlQhcA>?		M3e4eIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MmHCNlU5QTN{OUC=
MWCL-1	M1\1VmFxd3C2b4Ppd{BCe3OjeR?=	NGqxcHExNTFwNjFOwG0>	M2PIR\|I1KGh?		MWjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MnTPNlU5QTN{OUC=
MM.1s	M2rNb2Fxd3C2b4Ppd{BCe3OjeR?=	NG\me24xNTFwNjFOwG0>	MkW1NlQhcA>?		MWTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NX7UeIVJOjV6OUOyPVA>
HCT116	M1HZXGZ2dmO2aX;uJGF{e2G7	M{DZcFMwOTBizszN	NWDvWYVyOTMEoHlCpC=>	MX\EUXNQ	MUjpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	MWKyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO	NWX1W246TnWwY4Tpc44hSXO\|YYm=	NIrjOok{NzFyIN88US=>	M{[2TlEzyqCqwrC=	M{fyc2ROW09?	MnXWbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w	NHG3PHkzPTdzNUCyPC=>
HCT116	M2n3ZmZ2dmO2aX;uJGF{e2G7	MVexNEDPxE1?	MmrSNVLDqGkEoB?=	MnjzSG1UVw>?	NV\JRnpScW6lcnXhd4V{KEeIUD3MR\|NDKHC3bnP0ZS=>	MX[yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO	MVHGeY5kfGmxbjDBd5NigQ>?	M2rBe\|ExKM7:TR?=	NGXWUYUyOsLiaNMg	NF7ySmxFVVOR	NXnDTG04cW6lcnXhd4V{KEeIUD3MR\|NDKHC3bnP0ZS=>	MVmyOVcyPTB{OB?=
HCT116	MkHLRZV1d3CqYXf5JGF{e2G7	NHnLdXAyOCEQvF2=	M{DnXlEzyqCqwrC=	NUXLVG5CTE2VTx?=	NVL0VZJycW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	NEH3NoUzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO	M1LFUWF2fG:yaHHnfUBCe3OjeR?=	MUGxNEDPxE1?	M2PCPVEzyqCqwrC=	M4L4cGROW09?	MXLpcoR2[2W\|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=>	NWjlPY9iOjV5MUWwNlg>
U937	NWnKSlh1SXCxcITvd4l{KEG\|c3H5	NUnNNJhnOC5zMkWtNkDPxE1?	M4nkWFI1KGh?		MYflcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?=	MkTTNlU4OTRyMkS=
U937	NY\tUottSXCxcITvd4l{KEG\|c3H5	NIThbZcxNjVizszN	MV6yOEBp		Mnj1[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G\|cHHz[U0{KGG\|IIflcIwh[XNiTn;4ZUBt\X[nbB?=	M13jdlI2PzF2MEK0
HL-60 AAA-Bcl-2	MX3BdI9xfG:\|aYOgRZN{[Xl?	MkjSNE02KM7:TR?=	MVe0PEBp		NYLjVXdbUUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NVXTOXZQOjV5MUG0OlA>
HL-60 EEE-Bcl-2	NYL4[pl[SXCxcITvd4l{KEG\|c3H5	MXqwMVUh\|ryP	MVG0PEBp		NIX5PGhKSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUeyOVcyOTR4MB?=
U87	NVX5NndiTnWwY4Tpc44hSXO\|YYm=	MUW1NEDPxE1?	NFXUUVkzPCCq		MWfy[YR2[2W\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{	MonzNlU3Pjd4NkO=
K562	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGnkTYwyNTFyIN88US=>	MoLIOFghcA>?	NIXKT\|FFVVOR	MWrJR\|UxRTJ4Lkeg{txO	Ml\ONlU2QTZ3NkG=
K562/Mcl -1-IRESBim	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XycWlEPTB;OT6zJO69VQ>?	MXGyOVU{PTlyMB?=
K562/Bcl- 2-IRESBim	NFHxbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwM{Wg{txO	M3O3OlI2PTN3OUCw
Jurkat	M3LHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrZd3NKSzVyPUCuOlYh\|ryP	NFrZ[XIzPTV\|NUmwNC=>
JurkatΔBak	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{i4R2lEPTB-NUCg{txO	NGTFOWkzPTV\|NUmwNC=>
HL60/VCR	NI[yXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjaOFAyUUN3ME6xNFAh\|ryP	NHPqcWozPTV\|NUmwNC=>
Kasumi-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTBwMEGg{txO	NGfNbYUzPTV\|NUmwNC=>
Kasumi-1/ABT	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXDTWM2OD1yLkWxJO69VQ>?	MojUNlU2OzV7MEC=
THP-1	NXnLVFJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Hrb2lEPTB;MT6yO{DPxE1?	MW[yOVU{PTlyMB?=
U937	M1PRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTlN\|dtUUN3ME21MlI6KM7:TR?=	M13QXVI2PTN3OUCw
C1498	NYrUVZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzPdmxKSzVyPU[uNVMh\|ryP	NGXpXYczPTV\|NUmwNC=>
RPMI 8226	NFjXfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILtSlVKSzVyPUCuNlUh\|ryP	MXmyOVU{PTlyMB?=
MM.1S	NFvqb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXTW2pKSzVyPUCuOFAh\|ryP	NHf3cWgzPTV\|NUmwNC=>
NCI-H929	M3PVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfxNmlKSzVyPUG1MlIyKM7:TR?=	Mk\UNlU2OzV7MEC=
U266	NIHTTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DaWmlEPTB;MD62PEDPxE1?	NYHrR2Y1OjV3M{W5NFA>
MCF-7	NYrGdo5yS2WubDDWbYFjcWyrdImgRZN{[Xl?	NG\Dd4c2KM7:TR?=	Ml\yOFghcA>?	M2ju[GROW09?	NWrrSY5w\W6qYX7j[ZMhfGinIIPlcpNqfGm4aYT5JJRwKG:{IILh[IlifGmxbh?=	M4XY[VI2PDB7MUK0
MCF-7	MUHBdI9xfG:\|aYOgRZN{[Xl?	M{i0fVUh\|ryP	MYW0M\|I1NzR6IHi=	NYT2XY1NTE2VTx?=	NVLiT5RScW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA>	MmXlNlU1ODlzMkS=
MCF-7	NWHRRXRCTnWwY4Tpc44hSXO\|YYm=	MknxOUDPxE1?	MlrXNlQhcA>?	NXzMenIxTE2VTx?=	M3G3b4VvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	M4fUS\|I2PDB7MUK0
MDA-MB 231	M2T5dWZ2dmO2aX;uJGF{e2G7	M3\LcVUh\|ryP	M4ToOFI1KGh?	NHHFcnlFVVOR	NVvJPIdO\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi	NFO4NXIzPTRyOUGyOC=>
ZR-75-1	M3XDcWZ2dmO2aX;uJGF{e2G7	MlTOOUDPxE1?	M2LkclI1KGh?	MWjEUXNQ	NFWydHRmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB?	NYfXVod4OjV2MEmxNlQ>
A549	NV7Db2RCS2WubDDWbYFjcWyrdImgRZN{[Xl?	NH;BelgxNTJyIN88US=>	NF3MZYs4OiCq	NFPE[mFFVVOR	NIjZZ4Nl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NITEb3QzPTN6OEe2Ni=>
H1299	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NF3DOHMxNTJyIN88US=>	NHfvVmY4OiCq	M17FUWROW09?	NIP6PYNl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NIfRR5AzPTN6OEe2Ni=>
HO-8910	M2n2N2NmdGxiVnnhZoltcXS7IFHzd4F6	M{LKSVAuOjBizszN	MX[3NkBp	M{DQfGROW09?	MWTk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NEjJOZEzPTN6OEe2Ni=>
HT-29	MmPJR4VtdCCYaXHibYxqfHliQYPzZZk>	MlnqNE0zOCEQvF2=	NGDvPY84OiCq	NWm5WI5kTE2VTx?=	Mn7a[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	MnHuNlU{QDh5NkK=
HCT-116	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mk\GNE0zOCEQvF2=	MXK3NkBp	MnXQSG1UVw>?	M1j3WYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	MXyyOVM5QDd4Mh?=
A549	MX7BdI9xfG:\|aYOgRZN{[Xl?	M4HtSFIxKM7:TR?=	NFjEXG01QCCq	NI\iXGxFVVOR	MlXBbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	MVOyOVM5QDd4Mh?=
H1299	M4T2SWFxd3C2b4Ppd{BCe3OjeR?=	NYrWUHdKOjBizszN	MY[0PEBp	MmO4SG1UVw>?	MoTWbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	MmD6NlU{QDh5NkK=
Sc-1	NVP5[lZZS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHLy[ooxNjByMEGtNUDPxE1?	NU\GfYM{QTZiaB?=		Ml;i[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHjqWmMzPTN5M{WwPC=>
OcI-LY18	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUCwMlAxODFvMTFOwG0>	MmPRPVYhcA>?		MYHk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFHuUVAzPTN5M{WwPC=>
RL	M3[xcmNmdGxiVnnhZoltcXS7IFHzd4F6	NFfxZ5kxNjByMEGtNUDPxE1?	NVXxXlFnQTZiaB?=		MWXk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NEPzNXkzPTN5M{WwPC=>
RKO	NX\rZZB[S2WubDDWbYFjcWyrdImgRZN{[Xl?	M4e4bVAuOTBizszN	NH3sWVAzPOLCiXlCpC=>	MV3EUXNQ	MV7JR\|UxRuLCiUK15qCKyrWP	M3jNOlI2OzB2M{iz
Caco-2	M4XJR2NmdGxiVnnhZoltcXS7IFHzd4F6	M4TVR\|AuOTBizszN	NWjFTJM5OjUkgJnoxsA>	MVzEUXNQ	M3;JbGlEPTB;MUmuO-KBkcL3TR?=	MmHENlU{ODR\|OEO=
DLD1	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWqwMVExKM7:TR?=	MU[yOQKBkWkEoB?=	MlK3SG1UVw>?	NVnhXoV5UUN3ME2xPE44QOLCidM1US=>	NVrYV5JNOjV\|MESzPFM>
LS411N	NX;x[2FPS2WubDDWbYFjcWyrdImgRZN{[Xl?	NVPJZVRTOC1zMDFOwG0>	M3XBeFI16oDLaNMg	NHmwe5FFVVOR	NVi5cHNZUUN3ME2xNU41P+LCidM1US=>	NHzFTJYzPTNyNEO4Ny=>
SW620	NF;F[2FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mlm5NE0yOCEQvF2=	NHzBOHczPOLCiXlCpC=>	M3r4RmROW09?	NGToSWxKSzVyPUGyMlI16oDLwsXN	MUCyOVMxPDN6Mx?=
HCT116	MoK1R4VtdCCYaXHibYxqfHliQYPzZZk>	MmXRNE0yOCEQvF2=	MlfuNlTjiImqwrC=	Mny0SG1UVw>?	M3PPb2lEPTB;MkCuOFnjiIoEtV2=	MX2yOVMxPDN6Mx?=
HaCaT	M2LITmNmdGxiVnnhZoltcXS7IFHzd4F6	NEOycFYxNjFxMT:xNEDPxE1?	MYOyOEBp	MUHEUXNQ	M{nkV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M123UVI2OjFyN{m1
A5-RT3	MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mn:xNE4yNzFxMUCg{txO	MnfsNlQhcA>?	MlXRSG1UVw>?	MX3k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXSyOVIyODd7NR?=
HaCaT	NFu3OYJHfW6ldHnvckBCe3OjeR?=	Mn\SNVDjiIoQvF2=	MUCyOE81QCCq	NV:zS\|NPTE2VTx?=	NHzZSJRqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36=	NFPmblgzPTJzMEe5OS=>
A5-RT3	NYjibZg{TnWwY4Tpc44hSXO\|YYm=	NILYcFgyOOLCid88US=>	NIrWZXYzPC92ODDo	NHu0RnFFVVOR	NIfxT45qdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36=	NELyb2gzPTJzMEe5OS=>
A5-RT3	M3;aT2Z2dmO2aX;uJGF{e2G7	M{LXXFUh\|ryP	NE\UWnQ3KGh?	NYLBfXpFTE2VTx?=	MXzpcoR2[2W\|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy	MmG4NlUzOTB5OUW=
U266	M2jERmZ2dmO2aX;uJGF{e2G7	NFLwOWU2ODBxN{WwJI5O	NFjpS5IzPC92ODDo	M4fGNGROW09?	NYixeoVu\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	NWHTRWdxOjV{MEi4PFg>
RPMI8226	NFntd4RHfW6ldHnvckBCe3OjeR?=	M2fPc\|UxOC95NUCgcm0>	NGf4WmozPC92ODDo	NXzWWotTTE2VTx?=	Mlv0[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	Ml\qNlUzODh6OEi=
MM.1S	MXzGeY5kfGmxbjDBd5NigQ>?	NF3RZ2Y2ODBxN{WwJI5O	M3HJU\|I1NzR6IHi=	NFHSO5ZFVVOR	MYfkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2=	NF\KR3MzPTJyOEi4PC=>
Clone A	NX7iW5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7EcpYxNjMkgKO2NEDPxE1?	NFm0eXY4OiCq	NUnpOFFETE2VTx?=	M2XqbWlEPTB;Nz61JO69VQ>?	NVTjb5BPOjV{MEi4PFI>
CX-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PPVlAvOuLCk{[wJO69VQ>?	Mlf6O\|IhcA>?	MXPEUXNQ	MX7JR\|UxRTFwODFOwG0>	NXnUO2llOjV{MEi4PFI>
LS174T	NFLBZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKwMlLjiJN4MDFOwG0>	M2W4[FczKGh?	NWLyWZFkTE2VTx?=	NGLINWtKSzVyPUG4MlMh\|ryP	MX6yOVIxQDh6Mh?=
HT29	MVzBdI9xfG:\|aYOgRZN{[Xl?	NF34V2MyNzVxMUCg{txO	MWW0PEBp		NEiwTYdk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NXTMTXhuOjVzOUKxPFg>
SW480	NEDnbW1CeG:ydH;zbZMhSXO\|YYm=	NUPjU4pOOS93L{GwJO69VQ>?	M1nYTVQ5KGh?		NXuxV\|Jk[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NGG5WFIzPTF7MkG4PC=>
Colo205	NF6z[lZCeG:ydH;zbZMhSXO\|YYm=	NUjVSIZLOS93L{GwJO69VQ>?	M{XO[FQ5KGh?		NUnKe\|Rv[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NUTlfYZ{OjVzOUKxPFg>
Caco2	MUfBdI9xfG:\|aYOgRZN{[Xl?	NFPYe5gyNzVxMUCg{txO	NETYdo41QCCq		NYjRNohS[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1zVZ\|I2OTl{MUi4
PCI-13	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\CO\|IhcA>?	MlXvSG1UVw>?	NIPyN5NIUTVyPUG1JOKyKDFwODFOwG0>	NIn6UGIzPTF\|OUO4Oy=>
PCI-15B	NXO3b2dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{HoTVczKGh?	NHW0e4ZFVVOR	M4nMcGdKPTB;MUGgxtEhPC53IN88US=>	MkLqNlUyOzl\|OEe=
UM-SCC22B	NIm0cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYrIfm45PzJiaB?=	NVnzNY5MTE2VTx?=	M3PzfmdKPTB;MUmgxtEhOi57IN88US=>	NW\z[JBzOjVzM{mzPFc>
UM-SCC47	NUjRfnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkP2O\|IhcA>?	M1Wz[mROW09?	NH3MN4NIUTVyPUG5JOKyKDF{LkOg{txO	M4nVRVI2OTN7M{i3
93-VU-147T	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\WW\|czKGh?	M2HtS2ROW09?	Ml7VS2k2OD12LkOgxtEhOy53IN88US=>	MXWyOVE{QTN6Nx?=
UD-SCC2	NF\KOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[3NkBp	MkW2SG1UVw>?	NIP0TJFIUTVyPUK4JOKyKDJwOTFOwG0>	NF[2VFUzPTF\|OUO4Oy=>
UPCI:SCC90	NXzGcWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVO3NkBp	MYrEUXNQ	MWjHTVUxRTZwNjFCtUAyNjVizszN	MX6yOVE{QTN6Nx?=
RPMI-8226	M3rxTWNmdGxiVnnhZoltcXS7IFHzd4F6	MmjVNVI2NzJ3MD:1NFAhdk1?	M1H3e\|Q5cMLi	NYTsNXFRTE2VTx?=	M1vsUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MW[yOVAxQDJyMh?=
OPM-2	NHPUU3JE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NWP2UVBrOTJ3L{K1NE82ODBibl2=	M3vGO\|Q5cMLi	M2HycGROW09?	NFTlXlFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWeyOVAxQDJyMh?=
RPMI-8226	NH3zR\|NCeG:ydH;zbZMhSXO\|YYm=	M{W3V\|EzPS9{NUCvOVAxKG6P	NIe4Tlc1QGkEoB?=	NYfNO24yTE2VTx?=	NIfrfYdqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NVTtcWRHOjVyMEiyNFI>
OPM-2	Mk\ORZBweHSxc3nzJGF{e2G7	M4\yZVEzPS9{NUCvOVAxKG6P	NFnzUGw1QGkEoB?=	M3jLd2ROW09?	MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MWSyOVAxQDJyMh?=
COG-LL-319	NHnm[oJHfW6ldHnvckBCe3OjeR?=	M33ZdFExOCCwTR?=	NVjwR4huOS9\|L{[gbC=>	MnrKSG1UVw>?	Ml;jbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>?	NUm3NmN4OjR7NUG0O\|I>
RS4;11	NWDIR5ZXTnWwY4Tpc44hSXO\|YYm=	MmP3NVAxKG6P	NWPQUYFoOS9\|L{[gbC=>	NWfYUI11TE2VTx?=	NELU[VJqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen	NEG2RVczPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	+ Expand Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%) Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% Propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 120 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 120 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)